HC Wainwright & Co. Reiterates Buy on Phio Pharmaceuticals, Maintains $14 Price Target

Benzinga · 3d ago
HC Wainwright & Co. analyst Matthew Keller reiterates Phio Pharmaceuticals (NASDAQ:PHIO) with a Buy and maintains $14 price target.